APO Research
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Virus Infection Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Respiratory Virus Infection Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025193 pages

Choose your research edition.

Industry ResearchRespiratory Virus Infection Drugs Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Virus Infection Drugs Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Respiratory Virus Infection Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Virus Infection Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Virus Infection Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Respiratory Virus Infection Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Respiratory Virus Infection Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Respiratory Virus Infection Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Respiratory Virus Infection Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Respiratory Virus Infection Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Respiratory Virus Infection Drugs include Teva Pharmaceutical Industries Ltd., Sanofi, Merck and Co., Inc., GlaxoSmithKline plc, AstraZeneca, Orion Corporation, F. Hoffmann-La Roche Ltd., Cipla, Inc. and CHIESI Farmaceutici S.p.A., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Respiratory Virus Infection Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Respiratory Virus Infection Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Respiratory Virus Infection Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Respiratory Virus Infection Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Respiratory Virus Infection Drugs Segment by Company

Teva Pharmaceutical Industries Ltd.

Sanofi

Merck and Co., Inc.

GlaxoSmithKline plc

AstraZeneca

Orion Corporation

F. Hoffmann-La Roche Ltd.

Cipla, Inc.

CHIESI Farmaceutici S.p.A.

Boehringer Ingelheim International GmbH

Respiratory Virus Infection Drugs Segment by Type

Nasal Decongestants

Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)

Antibiotics

Cough Suppressants

Others

Respiratory Virus Infection Drugs Segment by Application

Retail Pharmacies

Drug Stores

Hospital Pharmacies

Clinics

Others

Respiratory Virus Infection Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Virus Infection Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Virus Infection Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Virus Infection Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Respiratory Virus Infection Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Respiratory Virus Infection Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Respiratory Virus Infection Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Respiratory Virus Infection Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Respiratory Virus Infection Drugs Industry Trends Table 2. Respiratory Virus Infection Drugs Industry Drivers Table 3. Respiratory Virus Infection Drugs Industry Opportunities and Challenges Table 4. Respiratory Virus Infection Drugs Industry Restraints Table 5. Global Respiratory Virus Infection Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Respiratory Virus Infection Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Respiratory Virus Infection Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Respiratory Virus Infection Drugs Sales Market Share by Manufacturers Table 9. Global Respiratory Virus Infection Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Respiratory Virus Infection Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Respiratory Virus Infection Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Respiratory Virus Infection Drugs Manufacturers, Product Type & Application Table 13. Global Respiratory Virus Infection Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Respiratory Virus Infection Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Nasal Decongestants Table 17. Major Manufacturers of Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) Table 18. Major Manufacturers of Antibiotics Table 19. Major Manufacturers of Cough Suppressants Table 20. Major Manufacturers of Others Table 21. Global Respiratory Virus Infection Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Respiratory Virus Infection Drugs Sales by Type (2021-2026) & (K Units) Table 23. Global Respiratory Virus Infection Drugs Sales by Type (2027-2032) & (K Units) Table 24. Global Respiratory Virus Infection Drugs Sales Market Share by Type (2021-2026) Table 25. Global Respiratory Virus Infection Drugs Sales Market Share by Type (2027-2032) Table 26. Global Respiratory Virus Infection Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Respiratory Virus Infection Drugs Revenue by Type (2021-2026) & (K Units) Table 28. Global Respiratory Virus Infection Drugs Revenue by Type (2027-2032) & (K Units) Table 29. Global Respiratory Virus Infection Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Respiratory Virus Infection Drugs Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Retail Pharmacies Table 32. Major Manufacturers of Drug Stores Table 33. Major Manufacturers of Hospital Pharmacies Table 34. Major Manufacturers of Clinics Table 35. Major Manufacturers of Others Table 36. Global Respiratory Virus Infection Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Respiratory Virus Infection Drugs Sales by Application (2021-2026) & (K Units) Table 38. Global Respiratory Virus Infection Drugs Sales by Application (2027-2032) & (K Units) Table 39. Global Respiratory Virus Infection Drugs Sales Market Share by Application (2021-2026) Table 40. Global Respiratory Virus Infection Drugs Sales Market Share by Application (2027-2032) Table 41. Global Respiratory Virus Infection Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Respiratory Virus Infection Drugs Revenue by Application (2021-2026) & (K Units) Table 43. Global Respiratory Virus Infection Drugs Revenue by Application (2027-2032) & (K Units) Table 44. Global Respiratory Virus Infection Drugs Revenue Market Share by Application (2021-2026) Table 45. Global Respiratory Virus Infection Drugs Revenue Market Share by Application (2027-2032) Table 46. Global Respiratory Virus Infection Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Respiratory Virus Infection Drugs Sales by Region (2021-2026) & (K Units) Table 48. Global Respiratory Virus Infection Drugs Sales Market Share by Region (2021-2026) Table 49. Global Respiratory Virus Infection Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Respiratory Virus Infection Drugs Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Respiratory Virus Infection Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Respiratory Virus Infection Drugs Sales by Country (2021-2026) & (K Units) Table 53. North America Respiratory Virus Infection Drugs Sales by Country (2027-2032) & (K Units) Table 54. Europe Respiratory Virus Infection Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Respiratory Virus Infection Drugs Sales by Country (2021-2026) & (K Units) Table 56. Europe Respiratory Virus Infection Drugs Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Respiratory Virus Infection Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Respiratory Virus Infection Drugs Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Respiratory Virus Infection Drugs Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Respiratory Virus Infection Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Respiratory Virus Infection Drugs Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Respiratory Virus Infection Drugs Sales by Country (2027-2032) & (K Units) Table 63. Global Respiratory Virus Infection Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Respiratory Virus Infection Drugs Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Respiratory Virus Infection Drugs Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Respiratory Virus Infection Drugs Revenue Market Share by Region (2021-2026) Table 67. Global Respiratory Virus Infection Drugs Revenue Market Share by Region (2027-2032) Table 68. Teva Pharmaceutical Industries Ltd. Company Information Table 69. Teva Pharmaceutical Industries Ltd. Business Overview Table 70. Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Product Portfolio Table 72. Teva Pharmaceutical Industries Ltd. Recent Development Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi Respiratory Virus Infection Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Sanofi Respiratory Virus Infection Drugs Product Portfolio Table 77. Sanofi Recent Development Table 78. Merck and Co., Inc. Company Information Table 79. Merck and Co., Inc. Business Overview Table 80. Merck and Co., Inc. Respiratory Virus Infection Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Merck and Co., Inc. Respiratory Virus Infection Drugs Product Portfolio Table 82. Merck and Co., Inc. Recent Development Table 83. GlaxoSmithKline plc Company Information Table 84. GlaxoSmithKline plc Business Overview Table 85. GlaxoSmithKline plc Respiratory Virus Infection Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. GlaxoSmithKline plc Respiratory Virus Infection Drugs Product Portfolio Table 87. GlaxoSmithKline plc Recent Development Table 88. AstraZeneca Company Information Table 89. AstraZeneca Business Overview Table 90. AstraZeneca Respiratory Virus Infection Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. AstraZeneca Respiratory Virus Infection Drugs Product Portfolio Table 92. AstraZeneca Recent Development Table 93. Orion Corporation Company Information Table 94. Orion Corporation Business Overview Table 95. Orion Corporation Respiratory Virus Infection Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Orion Corporation Respiratory Virus Infection Drugs Product Portfolio Table 97. Orion Corporation Recent Development Table 98. F. Hoffmann-La Roche Ltd. Company Information Table 99. F. Hoffmann-La Roche Ltd. Business Overview Table 100. F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Product Portfolio Table 102. F. Hoffmann-La Roche Ltd. Recent Development Table 103. Cipla, Inc. Company Information Table 104. Cipla, Inc. Business Overview Table 105. Cipla, Inc. Respiratory Virus Infection Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Cipla, Inc. Respiratory Virus Infection Drugs Product Portfolio Table 107. Cipla, Inc. Recent Development Table 108. CHIESI Farmaceutici S.p.A. Company Information Table 109. CHIESI Farmaceutici S.p.A. Business Overview Table 110. CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Product Portfolio Table 112. CHIESI Farmaceutici S.p.A. Recent Development Table 113. Boehringer Ingelheim International GmbH Company Information Table 114. Boehringer Ingelheim International GmbH Business Overview Table 115. Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Product Portfolio Table 117. Boehringer Ingelheim International GmbH Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Respiratory Virus Infection Drugs Distributors List Table 121. Respiratory Virus Infection Drugs Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Respiratory Virus Infection Drugs Product Image Figure 2. Global Respiratory Virus Infection Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Respiratory Virus Infection Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Respiratory Virus Infection Drugs Sales (2021-2032) & (K Units) Figure 5. Global Respiratory Virus Infection Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Respiratory Virus Infection Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Nasal Decongestants Image Figure 9. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) Image Figure 10. Antibiotics Image Figure 11. Cough Suppressants Image Figure 12. Others Image Figure 13. Global Respiratory Virus Infection Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Respiratory Virus Infection Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Respiratory Virus Infection Drugs Sales Market Share by Type (2021-2032) Figure 16. Global Respiratory Virus Infection Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Respiratory Virus Infection Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Respiratory Virus Infection Drugs Revenue Market Share by Type (2021-2032) Figure 19. Retail Pharmacies Image Figure 20. Drug Stores Image Figure 21. Hospital Pharmacies Image Figure 22. Clinics Image Figure 23. Others Image Figure 24. Global Respiratory Virus Infection Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Respiratory Virus Infection Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Respiratory Virus Infection Drugs Sales Market Share by Application (2021-2032) Figure 27. Global Respiratory Virus Infection Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Respiratory Virus Infection Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Respiratory Virus Infection Drugs Revenue Market Share by Application (2021-2032) Figure 30. North America Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Respiratory Virus Infection Drugs Sales Market Share by Country (2021-2032) Figure 32. U.S. Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Respiratory Virus Infection Drugs Sales Market Share by Country (2021-2032) Figure 37. Germany Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Respiratory Virus Infection Drugs Sales Market Share by Country (2021-2032) Figure 44. China Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Respiratory Virus Infection Drugs Sales Market Share by Country (2021-2032) Figure 52. Brazil Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Respiratory Virus Infection Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Respiratory Virus Infection Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Respiratory Virus Infection Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Respiratory Virus Infection Drugs Revenue (2021-2032) & (US$ Million) Figure 63. North America Respiratory Virus Infection Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Respiratory Virus Infection Drugs Revenue (2021-2032) & (US$ Million) Figure 65. Europe Respiratory Virus Infection Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Respiratory Virus Infection Drugs Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Respiratory Virus Infection Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Respiratory Virus Infection Drugs Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Respiratory Virus Infection Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Respiratory Virus Infection Drugs Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Respiratory Virus Infection Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Nasal Decongestants
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Antibiotics
  • Cough Suppressants
  • Others
Applications
  • Retail Pharmacies
  • Drug Stores
  • Hospital Pharmacies
  • Clinics
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Merck and Co., Inc.
  • GlaxoSmithKline plc
  • AstraZeneca
  • Orion Corporation
  • F. Hoffmann-La Roche Ltd.
  • Cipla, Inc.
  • CHIESI Farmaceutici S.p.A.
  • Boehringer Ingelheim International GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Respiratory Virus Infection Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Respiratory Virus Infection Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Respiratory Virus Infection Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Respiratory Virus Infection Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Respiratory Virus Infection Drugs Market Dynamics
  1. 2.1 Respiratory Virus Infection Drugs Industry Trends
  2. 2.2 Respiratory Virus Infection Drugs Industry Drivers
  3. 2.3 Respiratory Virus Infection Drugs Industry Opportunities and Challenges
  4. 2.4 Respiratory Virus Infection Drugs Industry Restraints
3 Respiratory Virus Infection Drugs Market by Manufacturers
  1. 3.1 Global Respiratory Virus Infection Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Respiratory Virus Infection Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Respiratory Virus Infection Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Respiratory Virus Infection Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Respiratory Virus Infection Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Respiratory Virus Infection Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Respiratory Virus Infection Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Respiratory Virus Infection Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Respiratory Virus Infection Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Respiratory Virus Infection Drugs Tier 1, Tier 2, and Tier 3
4 Respiratory Virus Infection Drugs Market by Type
  1. 4.1 Respiratory Virus Infection Drugs Type Introduction
  2. 4.1.1 Nasal Decongestants
  3. 4.1.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  4. 4.1.3 Antibiotics
  5. 4.1.4 Cough Suppressants
  6. 4.1.5 Others
  7. 4.2 Global Respiratory Virus Infection Drugs Sales by Type
  8. 4.2.1 Global Respiratory Virus Infection Drugs Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Respiratory Virus Infection Drugs Sales by Type (2021-2032)
  10. 4.2.3 Global Respiratory Virus Infection Drugs Sales Market Share by Type (2021-2032)
  11. 4.3 Global Respiratory Virus Infection Drugs Revenue by Type
  12. 4.3.1 Global Respiratory Virus Infection Drugs Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Respiratory Virus Infection Drugs Revenue by Type (2021-2032)
  14. 4.3.3 Global Respiratory Virus Infection Drugs Revenue Market Share by Type (2021-2032)
5 Respiratory Virus Infection Drugs Market by Application
  1. 5.1 Respiratory Virus Infection Drugs Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Drug Stores
  4. 5.1.3 Hospital Pharmacies
  5. 5.1.4 Clinics
  6. 5.1.5 Others
  7. 5.2 Global Respiratory Virus Infection Drugs Sales by Application
  8. 5.2.1 Global Respiratory Virus Infection Drugs Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Respiratory Virus Infection Drugs Sales by Application (2021-2032)
  10. 5.2.3 Global Respiratory Virus Infection Drugs Sales Market Share by Application (2021-2032)
  11. 5.3 Global Respiratory Virus Infection Drugs Revenue by Application
  12. 5.3.1 Global Respiratory Virus Infection Drugs Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Respiratory Virus Infection Drugs Revenue by Application (2021-2032)
  14. 5.3.3 Global Respiratory Virus Infection Drugs Revenue Market Share by Application (2021-2032)
6 Global Respiratory Virus Infection Drugs Sales by Region
  1. 6.1 Global Respiratory Virus Infection Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Respiratory Virus Infection Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Respiratory Virus Infection Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Respiratory Virus Infection Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Respiratory Virus Infection Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Respiratory Virus Infection Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Respiratory Virus Infection Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Respiratory Virus Infection Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Respiratory Virus Infection Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Respiratory Virus Infection Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Respiratory Virus Infection Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Respiratory Virus Infection Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Respiratory Virus Infection Drugs Revenue by Region
  1. 7.1 Global Respiratory Virus Infection Drugs Revenue by Region
  2. 7.1.1 Global Respiratory Virus Infection Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Respiratory Virus Infection Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Respiratory Virus Infection Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Respiratory Virus Infection Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Respiratory Virus Infection Drugs Revenue (2021-2032)
  8. 7.2.2 North America Respiratory Virus Infection Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Respiratory Virus Infection Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Respiratory Virus Infection Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Respiratory Virus Infection Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Respiratory Virus Infection Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Respiratory Virus Infection Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Respiratory Virus Infection Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries Ltd.
  2. 8.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Respiratory Virus Infection Drugs Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Merck and Co., Inc.
  14. 8.3.1 Merck and Co., Inc. Company Information
  15. 8.3.2 Merck and Co., Inc. Business Overview
  16. 8.3.3 Merck and Co., Inc. Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck and Co., Inc. Respiratory Virus Infection Drugs Product Portfolio
  18. 8.3.5 Merck and Co., Inc. Recent Developments
  19. 8.4 GlaxoSmithKline plc
  20. 8.4.1 GlaxoSmithKline plc Company Information
  21. 8.4.2 GlaxoSmithKline plc Business Overview
  22. 8.4.3 GlaxoSmithKline plc Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline plc Respiratory Virus Infection Drugs Product Portfolio
  24. 8.4.5 GlaxoSmithKline plc Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Respiratory Virus Infection Drugs Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Orion Corporation
  32. 8.6.1 Orion Corporation Company Information
  33. 8.6.2 Orion Corporation Business Overview
  34. 8.6.3 Orion Corporation Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Orion Corporation Respiratory Virus Infection Drugs Product Portfolio
  36. 8.6.5 Orion Corporation Recent Developments
  37. 8.7 F. Hoffmann-La Roche Ltd.
  38. 8.7.1 F. Hoffmann-La Roche Ltd. Company Information
  39. 8.7.2 F. Hoffmann-La Roche Ltd. Business Overview
  40. 8.7.3 F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Product Portfolio
  42. 8.7.5 F. Hoffmann-La Roche Ltd. Recent Developments
  43. 8.8 Cipla, Inc.
  44. 8.8.1 Cipla, Inc. Company Information
  45. 8.8.2 Cipla, Inc. Business Overview
  46. 8.8.3 Cipla, Inc. Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Cipla, Inc. Respiratory Virus Infection Drugs Product Portfolio
  48. 8.8.5 Cipla, Inc. Recent Developments
  49. 8.9 CHIESI Farmaceutici S.p.A.
  50. 8.9.1 CHIESI Farmaceutici S.p.A. Company Information
  51. 8.9.2 CHIESI Farmaceutici S.p.A. Business Overview
  52. 8.9.3 CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Product Portfolio
  54. 8.9.5 CHIESI Farmaceutici S.p.A. Recent Developments
  55. 8.10 Boehringer Ingelheim International GmbH
  56. 8.10.1 Boehringer Ingelheim International GmbH Company Information
  57. 8.10.2 Boehringer Ingelheim International GmbH Business Overview
  58. 8.10.3 Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Product Portfolio
  60. 8.10.5 Boehringer Ingelheim International GmbH Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Respiratory Virus Infection Drugs Value Chain Analysis
  2. 9.1.1 Respiratory Virus Infection Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Respiratory Virus Infection Drugs Production Mode & Process
  6. 9.2 Respiratory Virus Infection Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Respiratory Virus Infection Drugs Distributors
  9. 9.2.3 Respiratory Virus Infection Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst